Dewpoint Therapeutics Doses First Patient In Phase 1a/2a Trial Of DPTX3186, A First-In-Class Beta-Catenin Condensate Modulator, Targeting Advanced Solid Tumors Including Gastric Cancer

Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, announced that the first patient has been dosed in a Phase 1a/2a clinical trial evaluating its lead beta-catenin program in patients with advanced solid tumors, with a particular focus on gastric cancer.

The investigational therapy, DPTX3186, is a first-in-class small molecule designed to modulate beta-catenin signaling by altering its behavior within biomolecular condensates. Dysregulated beta-catenin signaling is a key oncogenic driver in multiple cancers, including gastric cancer, and has historically been considered undruggable through conventional approaches.

DPTX3186 has received both Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA), highlighting the significant unmet medical need in the targeted patient populations and the potential of the program to address it.

Isaac Klein, M.D., Ph.D., Chief Scientific Officer of Dewpoint Therapeutics, commented, “This milestone is a powerful validation of Dewpoint’s core scientific approach. We set out to demonstrate that understanding and modulating biomolecular condensates could unlock targets that were long considered undruggable. Dosing the first patient with a beta-catenin condensate modulator shows that this approach is not only biologically compelling but also clinically actionable.”

The Phase 1a/2a trial is a multi-center, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamic activity, and early signs of efficacy in patients with advanced or refractory solid tumors. The trial incorporates translational biomarker assessments to confirm target engagement and guide dose selection for subsequent clinical development.

Ameet Nathwani, M.D., Chief Executive Officer of Dewpoint Therapeutics, said, “Reaching the clinic with a beta-catenin modulator is a defining moment for Dewpoint. This achievement reflects years of foundational science translated through a disciplined and differentiated discovery engine. It reinforces our belief that condensate modulation represents a fundamentally new and scalable approach to developing medicines for serious diseases.”

Dewpoint’s beta-catenin program represents the first clinical validation of the company’s condensate-modulating platform, which is being applied across a growing pipeline of programs in oncology, neurology, and cardiometabolic diseases.